<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474471</url>
  </required_header>
  <id_info>
    <org_study_id>SOLVE</org_study_id>
    <nct_id>NCT03474471</nct_id>
  </id_info>
  <brief_title>A Trial on the Effects of Bronchoscopic Lung Volume Reduction in Severe Emphysema.</brief_title>
  <acronym>SOLVE</acronym>
  <official_title>A Prospective Randomized Controlled Trial on the Systemic Effects of Bronchoscopic Lung Volume Reduction in Patients With Severe Emphysema.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: The published clinical trials investigating the bronchoscopic lung volume&#xD;
      reduction, showing important patient-related improvements in efficacy, led to the&#xD;
      acknowledgement of the treatment in the GOLD-COPD2017 guidelines. Interaction with pulmonary&#xD;
      rehabilitation, impact on patient-reported outcomes, physical activity, and extrapulmonary&#xD;
      consequences are all topics to gain more insight in. This importantly, to further develop and&#xD;
      optimize this innovative and personalized therapy.&#xD;
&#xD;
      Objective: To study in detail the impact and optimal timing of pulmonary rehabilitation (PR)&#xD;
      on exercise physiology and patient-reported outcomes and the impact of the bronchoscopic lung&#xD;
      volume reduction treatment using endobronchial valves (EBV) on cardiopulmonary function,&#xD;
      metabolism and changes in body composition.&#xD;
&#xD;
      Study design: This study is a randomized controlled trial with 3 study-arms. Group 1 will&#xD;
      first follow a PR program and afterwards undergo the EBV treatment. Group 2 will first&#xD;
      undergo the EBV treatment and approximately 8 weeks later will follow a PR program. Group 3&#xD;
      will only undergo the EBV treatment (and can choose to follow a PR program after completing&#xD;
      the 6 month FU visit).&#xD;
&#xD;
      Study population: The study population exist of patients with severe emphysema who undergo a&#xD;
      bronchoscopic lung volume reduction treatment using one-way valves.&#xD;
&#xD;
      Intervention: Most patients will undergo a bronchoscopic lung volume reduction treatment&#xD;
      using endobronchial valves and a pulmonary rehabilitation program. One group of patient will&#xD;
      under a bronchoscopic lung volume reduction treatment using endobronchial valves and can&#xD;
      choose whether they also want to follow a pulmonary rehabilitation program afterwards.&#xD;
&#xD;
      Main study parameters: The main study parameter is the difference in change in endurance time&#xD;
      measured by an endurance cycle test between the EBV treatment group and the bronchoscopic&#xD;
      lung volume reduction + rehabilitation group (EBV+PR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: The published clinical trials investigating the bronchoscopic lung volume&#xD;
      reduction, showing important patient-related improvements in efficacy, led to the&#xD;
      acknowledgement of the treatment in the GOLD-COPD2017 guidelines. Interaction with pulmonary&#xD;
      rehabilitation, impact on patient-reported outcomes, physical activity, and extrapulmonary&#xD;
      consequences are all topics to gain more insight in. This importantly, to further develop and&#xD;
      optimize this innovative and personalized therapy.&#xD;
&#xD;
      Objective: To study in detail the impact and optimal timing of pulmonary rehabilitation (PR)&#xD;
      on exercise physiology and patient-reported outcomes and the impact of the bronchoscopic lung&#xD;
      volume reduction treatment using endobronchial valves (EBV) on cardiopulmonary function,&#xD;
      metabolism and changes in body composition.&#xD;
&#xD;
      Study design: This study is a randomized controlled trial with 3 study-arms. Group 1 will&#xD;
      first follow a PR program and afterwards undergo the EBV treatment. Group 2 will first&#xD;
      undergo the EBV treatment and approximately 8 weeks later will follow a PR program. Group 3&#xD;
      will only undergo the EBV treatment (and can choose to follow a PR program after completing&#xD;
      the 6 month FU visit).&#xD;
&#xD;
      Study population: The study population exist of patients with severe emphysema who undergo a&#xD;
      bronchoscopic lung volume reduction treatment using one-way valves.&#xD;
&#xD;
      Intervention: Most patients will undergo a bronchoscopic lung volume reduction treatment&#xD;
      using endobronchial valves and a pulmonary rehabilitation program. One group of patient will&#xD;
      under a bronchoscopic lung volume reduction treatment using endobronchial valves and can&#xD;
      choose whether they also want to follow a pulmonary rehabilitation program afterwards.&#xD;
&#xD;
      Main study parameters: The main study parameter is the difference in change in endurance time&#xD;
      measured by an endurance cycle test between the EBV treatment group and the bronchoscopic&#xD;
      lung volume reduction + rehabilitation group (EBV+PR).&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: This study has no major risks for the participating patients. The patients will&#xD;
      be exposed to additional exercise capacity and physical activity measurements, 3 additional&#xD;
      questionnaires, a CT scan of the quadriceps muscle, a DEXA scan and peripheral blood&#xD;
      collection. Furthermore, a subgroup of patients will be exposed to a cardiac MRI or muscle&#xD;
      and fat biopsies. Patient can directly benefit from the EBV treatment and the pulmonary&#xD;
      rehabilitation program. Indirect benefit might be achieved, because, at a group level the&#xD;
      investigators will learn more about this novel treatment for our severe emphysema patients&#xD;
      and will be able to further optimize this treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endurance time</measure>
    <time_frame>After 6 months</time_frame>
    <description>The difference in change in endurance time measured by an endurance cycle test between the EBV treatment group and the bronchoscopic lung volume reduction + rehabilitation group (EBV+PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary rehabilitation1</measure>
    <time_frame>After 6 months</time_frame>
    <description>• the difference between the EBV treatment group and the EBV+PR group in change in:&#xD;
Physical activity measured by accelerometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary rehabilitation2</measure>
    <time_frame>After 6 months</time_frame>
    <description>• the difference between the EBV treatment group and the EBV+PR group in change in:&#xD;
Lung function measured by bodyplehtysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary rehabilitation3</measure>
    <time_frame>After 6 months</time_frame>
    <description>• the difference between the EBV treatment group and the EBV+PR group in change in:&#xD;
Exercise capacity measured by an 6-minute walk distance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>After 6 months</time_frame>
    <description>• the change after EBV treatment in fatigue level measured by the CIS questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary function</measure>
    <time_frame>After 8 weeks</time_frame>
    <description>• the change after EBV treatment in RVEDVI as measured with cardiac MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolism and change in body composition</measure>
    <time_frame>After 8 weeks</time_frame>
    <description>• the change after EBV treatment in fat-free mass index, fat mass, and fat distribution measured by a dexa scan.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>Group 1:PR-EBV treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Follow a Pulmonary rehabilitation program PRIOR to the EBV treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: EBV treatment-PR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Follow a Pulmonary rehabilitation program AFTER the EBV treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: EBV treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Only EBV treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pulmonary rehabilitation</intervention_name>
    <description>Following a PR program</description>
    <arm_group_label>Group 1:PR-EBV treatment</arm_group_label>
    <arm_group_label>Group 2: EBV treatment-PR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EBV treatment</intervention_name>
    <description>Bronchoscopic lung volume reduction using endobronchial valves (EBV)</description>
    <arm_group_label>Group 1:PR-EBV treatment</arm_group_label>
    <arm_group_label>Group 2: EBV treatment-PR</arm_group_label>
    <arm_group_label>Group 3: EBV treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COPD.&#xD;
&#xD;
          -  FEV1 ≤45%pred AND FEV1/FVC &lt;70%.&#xD;
&#xD;
          -  TLC &gt;100%pred AND RV&gt;175%pred.&#xD;
&#xD;
          -  CAT ≥18.&#xD;
&#xD;
          -  &gt;50% emphysema destruction @-910HU.&#xD;
&#xD;
          -  &gt;95% complete major fissure measured by quantitative CT analysis.&#xD;
&#xD;
          -  Non-smoking &gt;6 months.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PaCO2&gt;8.0 kPa, or PaO2&lt;6.0kPa.&#xD;
&#xD;
          -  6-minute walk test &lt;160m.&#xD;
&#xD;
          -  Significant chronic bronchitis, bronchiectasis, or other infectious lung disease.&#xD;
&#xD;
          -  3 of more hospitalizations due to pulmonary infection within last 12 months before&#xD;
             baseline assessments&#xD;
&#xD;
          -  Previous lobectomy, LVRS, or lung transplantation.&#xD;
&#xD;
          -  LVEF&lt;45% and or RVSP&gt;50mmHg.&#xD;
&#xD;
          -  Anticoagulant therapy which cannot be weaned off prior to procedure.&#xD;
&#xD;
          -  Patient is significantly immunodeficient.&#xD;
&#xD;
          -  Involved in other pulmonary drug studies within 30 days prior to this study.&#xD;
&#xD;
          -  Pulmonary nodule which requires intervention&#xD;
&#xD;
          -  Any disease or condition that interferes with completion of initial or follow-up&#xD;
             assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk-Jan Slebos, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dirk-Jan Slebos, MD PhD</last_name>
    <phone>+31503616161</phone>
    <email>d.j.slebos@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk-Jan Slebos, MD PhD</last_name>
      <phone>+31503616161</phone>
      <email>d.j.slebos@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Dirk-Jan Slebos, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lowie Vanfleteren, MD Phd</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Dirk-Jan Slebos</investigator_full_name>
    <investigator_title>dr. D.J. Slebos</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

